Your browser is no longer supported. Please, upgrade your browser.
Settings
AWH Aspira Women's Health Inc. daily Stock Chart
AWH [NASD]
Aspira Women's Health Inc.
Index- P/E- EPS (ttm)-0.15 Insider Own1.70% Shs Outstand98.12M Perf Week-10.56%
Market Cap268.33M Forward P/E- EPS next Y- Insider Trans124.49% Shs Float50.86M Perf Month-12.71%
Income-14.70M PEG- EPS next Q- Inst Own27.30% Short Float13.04% Perf Quarter-47.52%
Sales4.60M P/S58.33 EPS this Y-8.50% Inst Trans27.51% Short Ratio7.19 Perf Half Y260.49%
Book/sh0.07 P/B36.29 EPS next Y- ROA-109.60% Target Price- Perf Year369.76%
Cash/sh0.10 P/C24.62 EPS next 5Y- ROE-178.00% 52W Range0.35 - 5.78 Perf YTD213.58%
Dividend- P/FCF- EPS past 5Y19.90% ROI-152.80% 52W High-52.25% Beta3.24
Dividend %- Quick Ratio3.00 Sales past 5Y12.50% Gross Margin31.30% 52W Low687.22% ATR0.29
Employees52 Current Ratio3.00 Sales Q/Q-36.40% Oper. Margin- RSI (14)45.01 Volatility8.00% 9.63%
OptionableYes Debt/Eq0.30 EPS Q/Q31.00% Profit Margin- Rel Volume0.80 Prev Close2.54
ShortableYes LT Debt/Eq0.22 EarningsAug 13 AMC Payout- Avg Volume922.96K Price2.76
Recom- SMA20-1.67% SMA50-19.63% SMA20027.60% Volume550,032 Change8.66%
Sep-15-20 05:01PM  
Sep-08-20 11:44AM  
Aug-22-20 10:01AM  
Aug-14-20 03:51PM  
Aug-13-20 04:01PM  
Jul-31-20 09:23AM  
Jul-08-20 06:30AM  
Jul-01-20 11:23AM  
Jun-29-20 08:00AM  
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. The company provides sells OVA1, Overa, and Ova1PLUS risk of malignancy tests for ovarian cancer. It also offers ASPiRA GenetiX, a genetic test for specific women's health diseases. In addition, the company owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, it is developing diagnostic algorithms, as well as a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. The company serves physicians, physician office laboratories, and hospital laboratories. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was founded in 1993 and is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHREIBER DAVIDDirectorSep 08Sale2.7850,000139,000185,018Sep 10 05:35 PM
SCHULER JACK W10% OwnerJul 01Buy3.502,285,7158,000,00325,394,517Jul 06 05:25 PM